Panacea Global, Inc.

Panacea Global, Inc.

November 14, 2013 08:30 ET

Panacea Global to Participate in 2013 World Cancer Leaders' Summit

TORONTO, ONTARIO--(Marketwired - Nov. 14, 2013) - Panacea Global, Inc. ("Panacea") (OTCBB:PANG), a biotechnology company focused on the discovery, development and commercialization of diagnostic products for the management of cancer, today announced that it will participate in the 2013 World Cancer Leaders' Summit, to be held on November 18-19, 2013 at the Mount Nelson Hotel and the Cape Town City Hall in South Africa.

Dr. Mahmood Moshiri, Panacea's President and CEO, will attend the Summit. Panacea is among a select group of biotechnology and pharmaceutical companies that will participate. The theme of this year's Summit is 'Closing the Cancer Divide by 2025', which highlights the urgent need to address inequalities in cancer control across national, international and regional boundaries.

This year's World Cancer Leaders' Summit is organized by the Union for International Cancer Control (UICC). The UICC works in partnership with corporations and organizations to support priority programmes that benefit the global cancer community and drive action on a global scale. Earlier this year, Panacea joined the UICC in an international partnership known as its Champions Programme. Other notable corporate partners include Sanofi, Bayer, Roche, and GSK, as well as a number of their member organizations.

"It's an honour to participate in this global event," said Dr. Moshiri. "As a UICC Champion, Panacea has a unique opportunity to contribute to cancer diagnosis and management on an international scale with our highly sensitive HAAH serum biomarker test. We welcome the opportunity to attend the World Cancer Leaders' Summit, which is an ideal forum for the exchange of information to address the ongoing, worldwide cancer epidemic."

About the World Cancer Leader's Summit (WCLS)

The World Cancer Leaders' Summit is an important, annual high-level policy meeting dedicated exclusively to furthering global cancer control. Key objectives of the World Cancer Leaders' Summit (WCLS) include raising awareness among leading decision makers to make cancer a global health priority, and creating a global force that galvanizes politicians and policy makers, and increases the visibility of cancer on the international public health agenda. For more information about WCLS, please visit

About Panacea Global

Panacea Global is a biotechnology company focused on the development and commercialization of diagnostic products for the management of cancer. Panacea has developed an accurate, timely, cost effective and non-invasive early cancer detection test to increase the quality of life of cancer patients and ultimately saving lives. Panacea's test is based on the detection of the human aspartyl (asparaginyl) β-hydroxylase (HAAH), a novel biomarker expressed in malignant cancer cells in patients' blood samples. Panacea Global has the exclusive worldwide (excluding the USA) rights to HAAH-based cancer tests. More information about Panacea Global (OTCBB:PANG) is available at

Forward-looking statements

Certain information contained in this document may include "forward-looking information". Without limiting the foregoing, the information and any forward-looking information may include statements regarding projects, costs, objectives and future returns of the Company or hypotheses underlying these items. In this document, words such as "may", "would", "could", "will", "likely", "believe", "expect", "anticipate", "intend", "plan", "estimate" and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. Forward-looking statements and information are based on information available at the time and/or the Company management's good-faith beliefs with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company's control. The Company does not intend, nor does it undertake, any obligation to update or revise any forward-looking information or statements contained in this document to reflect subsequent information, events or circumstances or otherwise, except as required by applicable laws.

Contact Information